# Ciwit

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ciwit-b-v

- Industry: Healthcare IT
- Headquarters: Amsterdam, Netherlands
- Website: www.castoredc.com
- Total disclosed funding: $57M
- Latest round: Series B (Jul 14, 2021)
- Investors on record: 5

## About

Ciwit B.V. specializes in eClinical solutions that enhance clinical research through efficient data management and patient engagement. Their innovative products support researchers in streamlining clinical trials, ensuring regulatory compliance, and improving patient experiences.Ciwit B.V. has developed a robust platform for managing clinical trial data, founded in 2011 in Amsterdam, Netherlands. The company was co-founded by Andy Wicks, Derk Arts, and Rob de Vries. They executed three deals with the latest funding round being a Series B, raising USD 45.00 mn on July 14, 2021, from investors including Eight Roads Ventures, F-Prime Capital, INKEF Capital, and Two Sigma Ventures. Derk Arts serves as the CEO.Ciwit B.V. offers an extensive suite of eClinical solutions, including Electronic Data Capture (EDC), Electronic Patient Reported Outcomes (ePRO), eConsent, and tools for Decentralized Clinical Trials (DCT). These products support the collection and integration of data from various sources, allowing researchers to efficiently manage clinical trials while adhering to regulatory standards. Their platform is tailored for clinical trials and real-world evidence studies, providing a user-friendly interface for study design and adaptation. Ciwit serves clients globally, including researchers, academic institutions, contract research organizations (CROs), and biotech and pharmaceutical companies, across North America, Europe, and Asia.Ciwit B.V. primarily generates revenue through subscription-based models for its eClinical services. Clients engage through direct partnerships, paying for access to the platform based on study scale and complexity. Pricing varies by user count, data integration needs, and specific services such as eConsent or ePRO. This model ensures predictable revenue as organizations depend on Ciwit’s solutions for compliant and efficient data management, backed by comprehensive customer support and training.Following the Series B funding of USD 45.00 mn in July 2021, Ciwit B.V. plans to enhance its product offerings and scale direct-to-patient trials on a global scale. The funding will be utilized to drive continued product development, focusing on innovative solutions tailored to meet the demands of evolving clinical research landscapes. Ciwit aims to expand its market presence, particularly targeting new geographic regions to broaden its client base and enhance operational capabilities.

## Funding rounds

- Series B, Jul 14, 2021, $45M — Eight Roads Ventures, F-Prime Capital, Two Sigma Investments, Inkef
- Series A, Aug 19, 2020, $12M — Two Sigma Investments, Hambrecht Capital, Inkef

## Investors

- Two Sigma Investments (https://capitalatlas.ai/funds/two-sigma-investments) — Series A, Series B
- Hambrecht Capital (https://capitalatlas.ai/funds/hambrecht-capital) — Series A
- Inkef (https://capitalatlas.ai/funds/inkef) — Series A, Series B
- Eight Roads Ventures (https://capitalatlas.ai/funds/eight-roads-ventures) — Series B
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series B